Lexaria Bioscience Reports DehydraTECH-Semaglutide Reduces Side Effects Compared to Rybelsus

Kelowna, British Columbia — July 28, 2025 — Leads & Copy — Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) announced partial positive interim results from its phase 1b study on DehydraTECH-semaglutide (DHT-semaglutide). The study, GLP-1-H24-4, is currently underway in Australia and focuses on DehydraTECH glucagon-like peptide-1 (GLP-1) study arms 2 and 5 relative to the Rybelsus® control study arm 4.

The interim results show a 36.5% reduction in overall side effects and a 43.5% reduction in gastrointestinal side effects with DHT-semaglutide compared to Rybelsus®. The DehydraTECH-GLP-1 study arms also demonstrated patient safety and tolerability consistent with the primary study endpoint.

CEO Richard Christopher stated that DehydraTECH continues to show superiority in reducing unwanted side effects compared to Rybelsus®, the only approved oral-based GLP-1 medication.

After eight weeks of treatment, Lexaria’s DehydraTECH-GLP-1 arms are tracking well in terms of safety and tolerability, relative to the Rybelsus® control arm, especially regarding reductions in gastrointestinal adverse events.

In the DHT-semaglutide study arm, 79.2% of participants experienced at least one adverse event, compared to 100% in the Rybelsus® arm. The total number of adverse events was 63.5% of the control arm for DHT-semaglutide and 93.8% for DHT-tirzepatide. Gastrointestinal adverse events were 56.5% of the control arm for DHT-semaglutide and 43.5% for DHT-tirzepatide.

The company also reported that average DHT-semaglutide weight loss results after 8 weeks are tracking similarly to the historical performance of Rybelsus® in the much larger Pioneer studies.

Additional 8-week interim Study data may or may not be released as it is more fully processed and understood in the weeks to come. The vast majority of laboratory-derived data, including a battery of additional safety, tolerability and efficacy parameter assessments beyond those summarized here, and all final results will not be available until near the end of calendar-2025. The Study is currently approaching the “last patient last visit” milestone and remains on schedule.

Investor Contact:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202

Source: Lexaria Bioscience Corp.